Systematic Review of Bispecific CAR-T Cell Therapy for Acute Leukemias, 2016-2025

Gabriela Valencia Putri Husodho's systematic review synthesizes evidence from nine studies on bispecific CAR-T cell therapy for acute leukemias. The review, following PRISMA guidelines, covers literature from PubMed, Scopus, and ProQuest published between 2016 and 2025. It concludes that bispecific CAR-T therapy is more effective than conventional CAR-T cells for managing acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Use Cases

• Summarizing clinical trial outcomes for bispecific CAR-T therapies based on the review's synthesis of nine studies.
• Identifying target antigens for CAR-T development in AML and ALL based on the described targets like CD123, CD33, CD19, and CD22.
• Comparing the efficacy and adverse effect profiles of bispecific versus conventional CAR-T cells based on the review's conclusions.
• Informing future research directions for CAR-T cell therapy based on the review's focus on developing diverse targets and advancing clinical trials.

Strengths

• Follows PRISMA guidelines for systematic review methodology.
• Covers a defined time range (2016-2025) and uses three major databases (PubMed, Scopus, ProQuest).
• Includes nine studies with in vivo, in vitro, and clinical trial designs, providing a multi-faceted evidence base.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is a single 684.3 KB DOCX file, indicating a limited scope focused on a review document rather than raw experimental data.

Provenance

Source

Gabriela Valencia Putri Husodho via figshare.

Collection Method

Systematic literature review following PRISMA guidelines.

Time Range

2016-2025

Freshness

Last updated 2026-04-23 04:21:56; freshness should be verified.

Geography

null